A patient has had a newly placed heart stent and is at an increased risk for developing a thrombus. Which type of medication would the nurse expect the doctor to prescribe for the patient after being discharged from the hospital?

A. Ferrous Sulfate: Ferrous sulfate is an iron supplement used to treat iron-deficiency anemia. It has no effect on preventing thrombus formation and is not indicated after stent placement. B. Erythropoietic Growth Factor: Erythropoietic growth factors stimulate red blood cell production in conditions like anemia. They do not prevent clot formation and are not relevant for post-stent care. C. Thrombolytic: Thrombolytics dissolve existing clots and are typically used in acute events, such as myocardial infarction or stroke. They are not prescribed routinely for long-term prevention after stent placement. D. Antiplatelet medication: Antiplatelet agents (e.g., aspirin, clopidogrel) inhibit platelet aggregation, reducing the risk of clot formation at the stent site. They are standard therapy after stent placement to prevent thrombosis and ensure patency of the stent.